Research suggests that emergency response personnel, recovery workers, law enforcement, and construction workers who reported to the World Trade Center disaster site were exposed to carcinogens that doubled their risk of developing myeloma.
Data from a subset of patients in an ongoing phase I study of Poseida Therapeutics’s lead program P-BCMA-ALLO1 showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.
